Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Regenxbio Inc
Regenxbio Inc logo

RGNX - Regenxbio Inc Reuters News

$40.14 -1.2  -2.8%

Last Trade - 03/03/21

Sector
Healthcare
RiskRating
Adventurous
Size
Mid Cap
Style
Momentum Trap
Market Cap £1.22bn
Enterprise Value £881.6m
Revenue £110.8m
Position in Universe 2314th / 6642
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions RGNX Dividends
Reuters News
All News Reuters News Company Announcements
BRIEF-Regenxbio Reports Q4 Loss Per Share Of $1.24
Mon 10:16pm News
BRIEF-Regenxbio Announces Positive Interim Phase I/IIa, Long-Term Follow-Up Data Of RGX-314 For Treatment Of Wet AMD
16th Feb News
BRIEF-Regenxbio Announces Closing Of Public Offering Of Common Stock
12th Jan News
BUZZ-Regenxbio Inc: Falls on discounted share offering
8th Jan News
BRIEF-Regenxbio Announces Pricing Of Public Offering Of Common Stock
8th Jan News
BRIEF-Regenxbio To Offer And Sell $175 Million Of Common Stock
6th Jan News
BRIEF-Regenxbio Announces Update On RGX-314, Pivotal Program For Treatment Of Wet AMD
5th Jan News
U.S. RESEARCH ROUNDUP-Apartment Income REIT, Paysign, Wesco International
23rd Dec '20 News
BRIEF-Regenxbio Announces Agreement To Monetize Portion Of Zolgensma Royalties For $200 Million
22nd Dec '20 News
BRIEF-REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE Trial of RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
10th Dec '20 News
BRIEF-Regenxbio Announces Positive Interim Data And Update For Phase I/II Trial Of RGX-121 For The Treatment Of MPS II
9th Dec '20 News
BRIEF-Regenxbio Inc Says Trial Will Evaluate One-Time, Direct-To-Cns Treatment For MPS I
1st Dec '20 News
BRIEF-Regenxbio Reports Third Quarter 2020 Financial Results And Operational Highlights
4th Nov '20 News
BRIEF-Regenxbio To Receive $80.0 Million Milestone Payment From Novartis AG
27th Oct '20 News
BRIEF-Regenxbio Announces Continued Progress, Expansion Of Clinical Development Program For Rgx-121 For Treatment Of Mucopolysaccharidosis Type II
30th Sep '20 News
BUZZ-Regenexbio: Down after partner Novartis' gene therapy setback
23rd Sep '20 News
BRIEF-REGENXBIO Announces Dosing Of First Patient In Phase II AAVIATE Trial Of RGX-314
9th Sep '20 News
BRIEF-Regenxbio Announces FDA Clearance Of IND For Phase II Trial Of Rgx-314
25th Aug '20 News
BRIEF-Regenxbio Reports Second Quarter 2020 Financial Results And Operational Highlights
6th Aug '20 News
BRIEF-REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update, Program Updates for RGX-314
4th Aug '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.